Satir, Tugce Munise
Nazir, Faisal Hayat
Vizlin-Hodzic, Dzeneta
Hardselius, Erik
Blennow, Kaj
Wray, Selina
Zetterberg, Henrik
Agholme, Lotta
Bergström, Petra
Article History
Received: 24 June 2019
Accepted: 30 December 2019
First Online: 17 January 2020
Change Date: 28 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: Kaj Blennow has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. Henrik Zetterberg has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. The other authors have no competing financial interest. The authors declare no non-financial competing interests.